te Boekhorst Paul Francis Olivier 4/A

What Happened

• Paul te Boekhorst, President & CEO and Director of Immucell Corp (ICCC), was granted an option award for 109,500 shares (reported as a derivative) effective January 27, 2026. The grant is reported at $0.00 per share (no immediate purchase price reported), with a reported monetary value of $0. This Form 4 is an amendment to correct the number of shares in the original report.

Key Details

• Transaction date and price: 2026-01-27; reported price $0.00 (derivative option award).
• Amount: 109,500 shares subject to the option.
• Shares owned after transaction: not specified in the provided filing summary.
• Filing status: Amended Form 4 filed 2026-03-23 to disclose the correct number of shares for the 1/27/2026 award.
• Notable footnotes:
  • F1: Amendment corrects previously reported share count for the option award.
  • F2: The option is intended to be treated as an incentive stock option to the extent allowed by the tax code, with any remainder treated as a nonqualified stock option. Vesting: 100% of the option vests only if the issuer’s net operating income for four consecutive calendar quarters equals or exceeds 300% of Immucell’s audited net operating income for its 2025 fiscal year.

Context

• This is an option grant (derivative award), not an immediate share purchase or sale, and its value to the insider depends on future vesting and potential exercise. Because vesting is contingent on a specific and material financial target (300% NOI over four consecutive quarters vs. 2025 audited NOI), the award may not vest for some time, so it does not reflect an immediate acquisition of tradable shares. The filing was amended to correct the reported quantity.